Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells $53,693.90 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 1,339 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $40.10, for a total transaction of $53,693.90. Following the sale, the insider directly owned 29,513 shares of the company’s stock, valued at approximately $1,183,471.30. The trade was a 4.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Castle Biosciences Stock Down 1.4%

Shares of CSTL opened at $39.34 on Friday. The company has a market capitalization of $1.15 billion, a P/E ratio of -87.42 and a beta of 1.06. Castle Biosciences, Inc. has a one year low of $14.59 and a one year high of $42.17. The business’s 50 day simple moving average is $37.66 and its 200-day simple moving average is $26.83. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.47 and a quick ratio of 6.31.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.32. The firm had revenue of $80.55 million during the quarter, compared to analysts’ expectations of $71.06 million. Castle Biosciences had a positive return on equity of 1.73% and a negative net margin of 3.56%. As a group, sell-side analysts predict that Castle Biosciences, Inc. will post 0.44 EPS for the current fiscal year.

Institutional Investors Weigh In On Castle Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. Farther Finance Advisors LLC boosted its stake in Castle Biosciences by 139,100.0% in the third quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock valued at $32,000 after acquiring an additional 1,391 shares during the last quarter. State of Alaska Department of Revenue bought a new stake in shares of Castle Biosciences during the 3rd quarter valued at $35,000. CWM LLC lifted its stake in shares of Castle Biosciences by 80.6% in the 3rd quarter. CWM LLC now owns 1,911 shares of the company’s stock valued at $44,000 after purchasing an additional 853 shares during the period. Jones Financial Companies Lllp boosted its position in shares of Castle Biosciences by 10,592.0% in the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after purchasing an additional 2,648 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of Castle Biosciences by 63.7% during the third quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock worth $57,000 after purchasing an additional 976 shares during the period. 92.60% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Robert W. Baird increased their price objective on shares of Castle Biosciences from $39.00 to $41.00 and gave the stock an “outperform” rating in a report on Tuesday, November 4th. Weiss Ratings reissued a “sell (d)” rating on shares of Castle Biosciences in a research note on Monday, December 29th. Canaccord Genuity Group boosted their price objective on shares of Castle Biosciences from $37.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Guggenheim upped their price objective on Castle Biosciences from $30.00 to $43.00 and gave the stock a “buy” rating in a report on Monday. Finally, Zacks Research cut Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 2nd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $43.17.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.